Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
The test, known as CRS7, is the first clinical test capable of predicting the likelihood of an HCV patient's risk of progressing to liver fibrosis and cirrhosis. According to the company, the availability of this test will substantially aid in the clinical management of HCV patients by ensuring they receive accurate, personalised treatment. The test has been clinically validated through multi-centre studies in North America.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.